查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1585643

生技药品开发与受託製造厂商市场：按类型、产品类型、适应症、服务类型、最终用户 - 2025-2030 年全球预测

Biologics Contract Development & Manufacturing Organization Market by Type (Mammalian, Non-mammalian), Product Type (Biologics, Biosimilars), Disease Indication, Service Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年生技药品开发和受託製造厂商市场价值为98.8亿美元，预计到2024年将达到105.9亿美元，复合年增长率为7.44%，到2030年将达到16.3亿美元。

生技药品开发和受託製造厂商市场在生物製药行业中发挥着至关重要的作用，提供细胞培养开发、生产流程和分析测试等基本服务。对生技药品CDMO 的需求源于向不具备内部能力的製药公司提供专业资源和专业知识的能力。该市场提供与单株抗体、疫苗、重组蛋白和基因治疗相关的应用，涵盖癌症、感染疾病和慢性病等广泛的治疗领域。从大型製药公司到小型生物技术新兴企业的最终用途提供者都利用 CDMO 的能力来加速药物开发并更快地将产品推向市场。

主要市场统计
基准年[2023] 98.8亿美元
预测年份 [2024] 105.9亿美元
预测年份 [2030] 163.5亿美元
复合年增长率（%） 7.44%

主要成长动力包括生技药品因其在治疗复杂疾病方面的精确性和有效性而不断增长的需求、生物加工技术的进步以及降低运营成本和加强对核心能力的关注的外包趋势，例如，生物製剂的增加。最近的机会在于个人化医疗，它使 CDMO 能够进入快速成长的客製化治疗领域，以及采用一次性技术，从而提供生产的灵活性和成本效率。公司可以透过投资先进的生物加工技术并扩大其服务范围以包括整合开发解决方案来利用这些趋势。

然而，挑战仍然存在，例如严格的监管要求，这可能导致高昂的合规成本和缓慢的上市时间。由于生技药品生产需求快速成长而出现的产能瓶颈也限制了市场成长，并可能影响生产计画。创新和研究应着重于透过提高製造的可扩展性和效率（例如连续生物加工技术的开发）来解决这些限制。此外，您可以透过改善与技术开发人员的协作以及投资数位转型（例如资料分析和人工智慧主导的见解）来推动业务成长。虽然这个市场本​​质上是竞争性的，但也有很大的合作潜力，需要平衡策略伙伴关係和创新以保持竞争力。

市场动态：快速发展的生技药品合约开发和受託製造厂商市场的关键市场洞察

供需的动态交互作用正在改变生技药品开发和受託製造厂商市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 对标靶治疗的细胞和基因治疗的需求不断增长
    • 在上游和下游加工中更多地采用一次性技术
    • 人们越来越关注新的生物治疗药物的开发
  • 市场限制因素
    • 对製造生技药品相关的产品品质和高成本的担忧
  • 市场机会
    • 透过生物製程技术的进步实现高效的大规模生产
    • 扩大研发创新投入，增加生技药品临床试验数量
  • 市场问题
    • 政府对 CDMO 组织的严格监管

波特的五力：驾驭生技药品开发和受託製造厂商市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解生技药品开发和受託製造厂商市场的外部影响

外部宏观环境因素在塑造生技药品开发和受託製造厂商市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解生技药品开发/受託製造厂商市场的竞争状况

对生技药品开发和受託製造厂商市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵生技药品开发与受託製造厂商市场供应商的绩效评估

FPNV 定位矩阵是评估生技药品开发和受託製造厂商市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：在生技药品开发和受託製造厂商市场中製定成功之路

对于旨在加强其在全球市场的影响力的公司来说，对生技药品开发和受託製造厂商市场进行策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 对标靶治疗的细胞和基因治疗的需求不断增加
      • 在上游和下游加工中更多地采用一次性技术
      • 越来越关注新型生物製药的开发
    • 抑制因素
      • 对生物製药製造相关产品品质和高成本的担忧
    • 机会
      • 生物加工技术的进步使高效的大规模生产成为可能。
      • 增加对研究和创新的投资并增加生技药品的临床测试
    • 任务
      • 针对 CDMO 组织的严格政府法规
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章生技药品开发与受託製造厂商市场：按类型

  • 介绍
  • 哺乳动物的
  • 非哺乳动物

第七章生技药品开发与受託製造厂商市场：依产品类型

  • 介绍
  • 生技药品
    • 反义和分子治疗
    • 单复製
    • 重组蛋白
    • 疫苗
  • 生物相似药

第八章生技药品开发/受託製造厂商市场：依适应症分类

  • 介绍
  • 心血管疾病
  • 血液疾病
  • 免疫疾病
  • 肿瘤学

第九章生技药品开发和受託製造厂商市场：按服务类型

  • 介绍
  • 细胞株开发
    • 哺乳动物的
    • 微生物
  • 製程开发
    • 下游
      • 杂质、分离、鑑定
      • 药物分析
      • 理化表征
    • 上游
      • 哺乳动物的
      • 微生物

第 10 章生技药品开发和受託製造厂商市场：按最终用户分类

  • 介绍
  • 生物製药公司
  • 研究所

第十一章 北美和南美生技药品开发和受託製造厂商市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太生技药品受託製造厂商市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲生技药品开发和受託製造厂商市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 三星生物製品扩大生物相似药 CDMO 产能
    • Catalent 扩展生物製剂服务平台
    • 旭化成集团美国生物製药 CDMO Bionova Scientific 扩大生产能力
  • 战略分析和建议

公司名单

  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc.
Product Code: MRR-957C47F9527F

The Biologics Contract Development & Manufacturing Organization Market was valued at USD 9.88 billion in 2023, expected to reach USD 10.59 billion in 2024, and is projected to grow at a CAGR of 7.44%, to USD 16.35 billion by 2030.

The Biologics Contract Development and Manufacturing Organization (CDMO) market is pivotal in the biopharmaceutical industry, providing essential services such as cell culture development, production processes, and analytical testing. The necessity of biologics CDMOs arises from their ability to offer specialized resources and expertise to pharmaceutical companies, which may lack in-house capabilities. This market serves applications related to monoclonal antibodies, vaccines, recombinant proteins, and gene therapies, catering to a wide array of therapeutic areas including oncology, infectious diseases, and chronic conditions. End-use providers range from large pharmaceutical firms to small biotech startups, leveraging CDMO capabilities to accelerate drug development and bring products to market faster.

KEY MARKET STATISTICS
Base Year [2023] USD 9.88 billion
Estimated Year [2024] USD 10.59 billion
Forecast Year [2030] USD 16.35 billion
CAGR (%) 7.44%

Key growth drivers include the escalating demand for biologics due to their precision and efficacy in treating complex diseases, technological advancements in bioprocessing, and the increasing trend towards outsourcing to reduce operational costs and enhance focus on core competencies. Recent opportunities lie in personalized medicine, where CDMOs can tap into the burgeoning field of tailored therapies, and in the adoption of single-use technology, which offers flexibility and cost-effectiveness in production. Companies could capitalize on these trends by investing in advanced bioprocessing technologies and expanding service offerings to include integrated development solutions.

However, challenges persist, such as stringent regulatory requirements, which necessitate high compliance costs and can delay time-to-market. Market growth is also constrained by capacity bottlenecks stemming from the rapid increase in biologics production demand, which can impact production timelines. Innovation and research should focus on addressing these limitations by enhancing manufacturing scalability and efficiency, such as through the development of continuous bioprocessing technologies. Additionally, improving collaborations with technology developers and investing in digital transformations like data analytics and AI-driven insights can foster business growth. The nature of this market is competitive yet ripe with collaboration potential, necessitating a balance between strategic partnership and technological innovation to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Development & Manufacturing Organization Market

The Biologics Contract Development & Manufacturing Organization Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand for cell and gene therapies for targeted treatment
    • Growing adoption of single-use technologies in upstream and downstream processing
    • Increasing focus on developing novel biotherapeutics
  • Market Restraints
    • Concern regarding product quality and high costs associated with biologics products manufacturing
  • Market Opportunities
    • Advancement in bioprocessing technologies enabled efficient large-scale production
    • Growing investment in research and innovation and rising numbers of clinical trials for biologics
  • Market Challenges
    • Strict governmental laws and regulations for CDMO organizations

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Development & Manufacturing Organization Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Development & Manufacturing Organization Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Development & Manufacturing Organization Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Development & Manufacturing Organization Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Development & Manufacturing Organization Market

A detailed market share analysis in the Biologics Contract Development & Manufacturing Organization Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Development & Manufacturing Organization Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Development & Manufacturing Organization Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Development & Manufacturing Organization Market

A strategic analysis of the Biologics Contract Development & Manufacturing Organization Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Development & Manufacturing Organization Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Development & Manufacturing Organization Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Mammalian and Non-mammalian.
  • Based on Product Type, market is studied across Biologics and Biosimilars. The Biologics is further studied across Antisense & Molecular Therapy, Monoclonal, Recombinant Proteins, and Vaccines.
  • Based on Disease Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, and Oncology.
  • Based on Service Type, market is studied across Cell Line Development and Process Development. The Cell Line Development is further studied across Mammalian and Microbial. The Process Development is further studied across Downstream and Upstream. The Downstream is further studied across Impurity, Isolation, & Identification, Pharmaceutical Analysis, and Physicochemical Characterization. The Upstream is further studied across Mammalian and Microbial.
  • Based on End-User, market is studied across Biopharmaceutical Companies and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand for cell and gene therapies for targeted treatment
      • 5.1.1.2. Growing adoption of single-use technologies in upstream and downstream processing
      • 5.1.1.3. Increasing focus on developing novel biotherapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. Concern regarding product quality and high costs associated with biologics products manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in bioprocessing technologies enabled efficient large-scale production
      • 5.1.3.2. Growing investment in research and innovation and rising numbers of clinical trials for biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict governmental laws and regulations for CDMO organizations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Contract Development & Manufacturing Organization Market, by Type

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Non-mammalian

7. Biologics Contract Development & Manufacturing Organization Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biologics
    • 7.2.1. Antisense & Molecular Therapy
    • 7.2.2. Monoclonal
    • 7.2.3. Recombinant Proteins
    • 7.2.4. Vaccines
  • 7.3. Biosimilars

8. Biologics Contract Development & Manufacturing Organization Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Oncology

9. Biologics Contract Development & Manufacturing Organization Market, by Service Type

  • 9.1. Introduction
  • 9.2. Cell Line Development
    • 9.2.1. Mammalian
    • 9.2.2. Microbial
  • 9.3. Process Development
    • 9.3.1. Downstream
      • 9.3.1.1. Impurity, Isolation, & Identification
      • 9.3.1.2. Pharmaceutical Analysis
      • 9.3.1.3. Physicochemical Characterization
    • 9.3.2. Upstream
      • 9.3.2.1. Mammalian
      • 9.3.2.2. Microbial

10. Biologics Contract Development & Manufacturing Organization Market, by End-User

  • 10.1. Introduction
  • 10.2. Biopharmaceutical Companies
  • 10.3. Research Laboratories

11. Americas Biologics Contract Development & Manufacturing Organization Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Biologics Contract Development & Manufacturing Organization Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Biologics Contract Development & Manufacturing Organization Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Biosimilar CDMO Capacity Increased in Samsung Biologics
    • 14.3.2. Catalent expands its biologics services platform
    • 14.3.3. Bionova Scientific, U.S. biologics CDMO of the Asahi Kasei Group, expands manufacturing capacity
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Abzena Ltd.
  • 3. Aenova Holding GmbH
  • 4. AGC Biologics GmbH
  • 5. Avid Bioservices, Inc.
  • 6. Binex Co. Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Cambrex Corporation
  • 9. Catalent, Inc.
  • 10. Emergent BioSolutions, Inc.
  • 11. Fujifilm Holdings Corporation
  • 12. Icon PLC
  • 13. JSR Life Sciences, LLC
  • 14. Lonza Group AG
  • 15. Parexel International Corporation
  • 16. ProBioGen AG
  • 17. Recipharm AB
  • 18. Rentschler Biopharma SE
  • 19. Samsung Biologics
  • 20. Takeda Pharmaceutical Company Limited
  • 21. Thermo Fisher Scientific, Inc.
  • 22. Toyobo Co., Ltd.
  • 23. WuXi Biologics Inc.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTISENSE & MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMPURITY, ISOLATION, & IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHYSICOCHEMICAL CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UP